

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10



FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 1

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001

Confirmation No.: 8022

Art Unit: 1647

Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended -- METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON --

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
/JS/	DA-01	6,875,748	April 5, 2005	Manthorpe, et al.			
	DA-						

FOREIGN PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
/JS/	DB-01	WO 00/40273A2	13 July 2000	WIPO/PCT			
/JS/	DB-02	WO 00/40273A3	13 July 2000	WIPO/PCT			


OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	DC-	
	DC-	

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10



FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 1

In the Application of: Stanford Mark Moran

Confirmation No.: 8022

Serial No.: 10/004,118

Art Unit: 1647

Filed: 30 October 2001

Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended – METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON –

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	EA-						

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
	EB-						

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
/JS/	EC-01	ZHENG et S. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis" Beijing Medical Journal 13(2):80-81 (1998). WITH ACCOMPANYING ENGLISH TRANSLATION.
/JS/	EC-02	ZHANG et al. "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis" Journal of Clinical Pediatrics 14(2):83-84 (1996). WITH ACCOMPANYING ENGLISH TRANSLATION.
/JS/	EC-03	ZHANG et al. "Efficacy Observations of Different Dosages of Interferon to Treat 150 Hepatitis B Carriers" Current Physician 2(12):45-46 (1997). WITH ACCOMPANYING ENGLISH TRANSLATION.

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007


EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

Sheet 1 of 1



In the Application of: Stanford Mark Moran

Confirmation No.: 8022

Serial No.: 10/004,118

Art Unit: 1647

Filed: 30 October 2001

Examiner: Seharaseyon, J.

Title: Previously "Method for short-term and long-term drug dosimetry," as currently amended -- METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON --

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	FA-						

FOREIGN PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
	FB-						

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
/JS/	FC-01	The IFNB Multiple Sclerosis Group, "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis," Neurology 43:655-661 (1993)
	FC-	
	FC-	

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10



FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 6

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001  
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022  
Art Unit: 1647  
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Name	Date	Class	Sub Class	Filing Date
/JS/	A-01	4,211,771	Witkowski et al.	07/08/1980			
	A-02	4,695,623	Stabinsky	09/22/1987			
	A-03	4,727,138	Goeddel et al.	02/23/1988			
	A-04	4,762,791	Goeddel et al.	08/09/1988			
	A-05	4,820,638	Swetly et al.	04/11/1989			
	A-06	4,845,196	Cowling	07/04/1989			
	A-07	4,897,471	Stabinsky	01/30/1990			
	A-08	4,915,954	Ayer et al.	04/10/1990			
	A-09	4,917,895	Lee et al.	04/17/1990			
	A-10	4,929,554	Goeddel et al.	05/29/1990			
	A-11	4,976,966	Theeuwes et al.	12/11/1990			
	A-12	5,004,689	Fiers et al.	04/02/1991			
	A-13	5,112,614	Magruder et al.	05/12/1992			
	A-14	5,120,832	Goeddel et al.	06/09/1992			
	A-15	5,221,278	Linkwitz et al.	06/22/1993			
	A-16	5,231,176	Goeddel et al.	07/27/1993			
	A-17	5,318,558	Linkwitz et al.	06/07/1994			

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 2 of 6

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001  
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022  
Art Unit: 1647  
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Name	Date	Class	Sub Class	Filing Date
/JS/	A-18	5,324,280	Wong et al.	06/28/1994			
	A-19	5,368,863	Eckenhoff et al.	11/29/1994			
	A-20	5,413,572	Wong et al.	05/09/1995			
	A-21	5,443,459	Wong et al.	08/22/1995			
	A-22	5,529,914	Hubbell et al.	06/25/1996			
	A-23	5,543,156	Roorda et al.	08/06/1996			
	A-24	5,574,137	Gray et al.	11/12/1996			
	A-25	5,602,010	Hauptmann et al.	02/11/1997			
	A-26	5,660,847	Magruder et al.	08/26/1997			
	A-27	5,690,925	Gray et al.	11/25/1997			
	A-28	5,728,396	Peery et al.	03/17/1998			
	A-29	5,795,779	McCormick et al.	08/18/1998			
	A-30	5,807,876	Armistead et al.	09/15/1998			
	A-31	5,858,746	Hubbell et al.	01/12/1999			
	A-32	5,939,286	Johnson et al.	08/17/1999			
	A-33	5,985,305	Peery et al.	11/16/1999			
↓	A-34	6,113,938	Chen et al.	09/05/2000			

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 3 of 6

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001  
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022  
Art Unit: 1647  
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Name	Date	Class	Sub Class	Filing Date
/JS/	A-35	6,129,761	Hubbell	10/10/2000			
/JS/	A-36	6,204,022	Johnson et al.	03/20/2001			
/JS/	A-37	6,172,046	Albrecht	01/09/2001			

FOREIGN PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
/JS/	B-01	WO 03/030923 A1	17-Apr-2003	WIPO/PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
/JS/	C-01	ADAMSON et al., "Phase I trial and pharmacokinetic study of all- <i>trans</i> -retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer" J Clin Oncol (1997) Nov; 15(11):3330-3337
/JS/	C-02	BAILON et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C" Bioconjugate Chemistry (2001), 12(2):195-202

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 4 of 6

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001  
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022  
Art Unit: 1647  
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
/JS/	C-03	DORR et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days" J Interferon Res (1988); 8:717-725
	C-04	FRANCHETTI et al., "Furanfuran and Thiophenfurin: Two Novel Tiazofuran Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase" Journal of Medicinal Chemistry (1995); 38(19):3829-3837
	C-05	GAUSE et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer" J Clin Oncol (1996) Aug; 14(8):2234-2241
	C-06	GOSLAND et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha" Cancer Chemother Pharmacol (1995); 37(1-2):39-46
	C-07	HEATHCOTE et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis" New England Journal of Medicine (2000); 343(23):1673-1680
	C-08	HORTON et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999)
	C-09	HUBEL et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia (1997) Dec; 11 Suppl 5:S47-S51
	C-10	IACOBELLI et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer" Am J Clin Oncol (1995); 18(1):27-31
	C-11	ISHIWATA et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs" (1998); J Vet Med Sci 60(8):911-917
↓	C-12	KIRKWOOD et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684" J Clin Oncol (1996); 14(1):7-17

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 5 of 6

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001  
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022  
Art Unit: 1647  
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
/JS/	C-13	MOTZER et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma" Journal of Clinical Oncology (2001); 19(5):1312-1319
	C-14	NEUMANN et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy" Science 282 (1998): 103-107.
	C-15	RAJKUMAR et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma" Int J Radiat Oncol Biol Phys (1998) Jan 15; 40(2):297-302
	C-16	ROTH et al., "High Dose Etrretinate and Interferon-alpha--A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas" Acta Oncol (1999); 38(5):613-617
	C-17	SULKOWSKI et al., "Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study" Gastroenterology (2000); 118(4_Suppl_2), Abstract 236
	C-18	TALPAZ et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia" Blood (2001); 98(6):1708-1713
	C-19	TRUDEAU et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer" Cancer Chemother Pharmacol (1995); 35(6):496-500
	C-20	VOKES et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest" Cancer Chemother Pharmacol (1995); 35(4):304-312
	C-21	ZEUZEM et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C" New England Journal of Medicine (2000), 343(23):1666-1672
	C-22	InterMune® Inc. Infergen® (Interferon alfacon-1). 2002
	C-23	Hoffmann-La Roche Inc. Pegasys® (peginterferon alfa-2a). 2002
	C-24	Roche Pharmaceuticals. ROFERON®-A (Interferon alfa-2a, recombinant). 2003
✓	C-25	Schering Corporation. Intron® A for Injection. 2001

Examiner: /Jegatheesan Seharaseyon/

08/20/2007  
Date Considered: \_\_\_\_\_

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 6 of 6

In the Application of: Stanford Mark Moran  
Serial No.: 10/004,118  
Filed: 30 October 2001  
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022  
Art Unit: 1647  
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
/JS/	C-26	Schering Corporation. PEG-Intron™ (Peginterferon alfa-2b). Powder for Injection. 2003

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 08/20/2007

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.